| Q36960608 | A novel approach to evaluate the immunogenicity of viral antigens of clinical importance in HLA transgenic murine models |
| Q34815702 | A panel of artificial APCs expressing prevalent HLA alleles permits generation of cytotoxic T cells specific for both dominant and subdominant viral epitopes for adoptive therapy. |
| Q45370775 | Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirus-specific CD8+ T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation |
| Q81398931 | Adoptive transfer of antigen-specific T-cells of donor type for immunotherapy of viral infections following allogeneic hematopoietic cell transplants |
| Q37077310 | Age-associated increase of low-avidity cytomegalovirus-specific CD8+ T cells that re-express CD45RA |
| Q39592383 | Altered decamer and nonamer from an HLA-A0201-restricted epitope of Survivin differentially stimulate T-cell responses in different individuals |
| Q46678222 | Analysis of the human cytomegalovirus pp65-directed T-cell response in healthy HLA-A2-positive individuals |
| Q35757381 | CMV reactivation drives posttransplant T-cell reconstitution and results in defects in the underlying TCRβ repertoire |
| Q35842287 | Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant |
| Q47111092 | Comprehensive Analysis of Cytomegalovirus pp65 Antigen-Specific CD8+ T Cell Responses According to Human Leukocyte Antigen Class I Allotypes and Intraindividual Dominance |
| Q28548093 | Comprehensive Analysis of the Naturally Processed Peptide Repertoire: Differences between HLA-A and B in the Immunopeptidome |
| Q39895985 | Cross-presentation of HCMV chimeric protein enables generation and measurement of polyclonal T cells |
| Q28731516 | Development of a humanized HLA-A2.1/DP4 transgenic mouse model and the use of this model to map HLA-DP4-restricted epitopes of HBV envelope protein |
| Q53660426 | Evaluation of cytomegalovirus-specific cytotoxic T-lymphocytes in patients with the HLA-A*02 or HLA-A*24 phenotype undergoing hematopoietic stem cell transplantation. |
| Q27322650 | Ex vivo SIV-specific CD8 T cell responses in heterozygous animals are primarily directed against peptides presented by a single MHC haplotype |
| Q40454655 | Ex vivo induction of viral antigen-specific CD8 T cell responses using mRNA-electroporated CD40-activated B cells. |
| Q57209233 | Extensive major histocompatibility complex class I binding promiscuity for Mycobacterium tuberculosis TB10.4 peptides and immune dominance of human leucocyte antigen (HLA)-B*0702 and HLA-B*0801 alleles in TB10.4 CD8 T-cell responses |
| Q79915030 | Functional analysis of cytomegalovirus-specific T lymphocytes compared to tetramer assay in patients undergoing hematopoietic stem cell transplantation |
| Q33262230 | HLA Alleles Associated with Delayed Progression to AIDS Contribute Strongly to the Initial CD8(+) T Cell Response against HIV-1. |
| Q39156328 | Heat shock protein 70/peptide complexes: potent mediators for the generation of antiviral T cells particularly with regard to low precursor frequencies |
| Q35192655 | High-functional-avidity cytotoxic T lymphocyte responses to HLA-B-restricted Gag-derived epitopes associated with relative HIV control |
| Q51984521 | Human CD8+ cytotoxic T cell responses to adenovirus capsid proteins. |
| Q40585877 | Identification of a naturally processed cytotoxic CD8 T-cell epitope of coxsackievirus B4, presented by HLA-A2.1 and located in the PEVKEK region of the P2C nonstructural protein |
| Q28072627 | Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation |
| Q45710911 | Immunization with Th-CTL Fusion Peptide and Cytosine-Phosphate-Guanine DNA in Transgenic HLA-A2 Mice Induces Recognition of HIV-Infected T Cells and Clears Vaccinia Virus Challenge |
| Q39676680 | Immunogenicity of a recombinant lentiviral vector carrying human telomerase tumor antigen in HLA-B*0702 transgenic mice |
| Q30373149 | Immunogenicity of virosomal adjuvanted trivalent influenza vaccination in allogeneic stem cell transplant recipients. |
| Q35958223 | Immunotherapy with Donor T Cells Sensitized with Overlapping Pentadecapeptides for Treatment of Persistent Cytomegalovirus Infection or Viremia |
| Q35268996 | Insights into HLA-restricted T cell responses in a novel mouse model of dengue virus infection point toward new implications for vaccine design |
| Q36238731 | Measles Virus Epitope Presentation by HLA: Novel Insights into Epitope Selection, Dominance, and Microvariation |
| Q37504394 | Novel strategies for adoptive therapy following HLA disparate transplants |
| Q38899411 | Preconditioning therapy with lentiviral vector-programmed dendritic cells accelerates the homeostatic expansion of antigen-reactive human T cells in NOD.Rag1-/-.IL-2rγc-/- mice |
| Q34743762 | Presentation of an immunodominant immediate-early CD8+ T cell epitope resists human cytomegalovirus immunoevasion |
| Q40133430 | Rapid identification of an HLA-B*1501-restricted vaccinia peptide antigen |
| Q38877091 | Sequence-based human leukocyte antigen-B typing of patients infected with Ebola virus in Uganda in 2000: identification of alleles associated with fatal and nonfatal disease outcomes |
| Q34524941 | Sequential anti-cytomegalovirus response monitoring may allow prediction of cytomegalovirus reactivation after allogeneic stem cell transplantation |
| Q53657386 | T cell control of primary and latent cytomegalovirus infections in healthy subjects. |
| Q38514497 | T-cell depleted allogeneic hematopoietic cell transplants as a platform for adoptive therapy with leukemia selective or virus-specific T-cells |
| Q90682104 | The Presence of a CMV Immunodominant Allele in the Recipient Is Associated With Increased Survival in CMV Positive Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation |
| Q92735537 | Therapeutic advantages provided by banked virus-specific T-cells of defined HLA-restriction |
| Q35751946 | Vaccine properties of a novel marker gene-free recombinant modified vaccinia Ankara expressing immunodominant CMV antigens pp65 and IE1. |
| Q64375296 | Virus-Specific T Cells: Current and Future Use in Primary Immunodeficiency Disorders |
| Q38797555 | Virus-specific T-cell banks for 'off the shelf' adoptive therapy of refractory infections |